Abstract
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1794-1797 |
| Number of pages | 4 |
| Journal | Clinical Infectious Diseases |
| Volume | 66 |
| Issue number | 11 |
| DOIs | |
| State | Published - May 17 2018 |
Funding
continuation of standard 3-drug maintenance therapy. This was supported by the FDA snapshot analyses at weeks 24 and 48. Financial support. This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU). ViiV Healthcare and GlaxoSmithKline provided funding and the study drugs. Potential conflicts of interest. B. O. T. has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau and has received grant funding to his institution from ViiV/ GlaxoSmithKline (GSK). V. C. M., C. J. F., C. A. B., T. W., S. L. K., J. C., and P. E. S. have received grant funding for this study to their institutions through NU from ViiV/GSK. C. B. M. has received a consulting fee from NU. C. J. F. has received payment for service on the Clinical Care Options speakers bureau and grant funding to his institution from ViiV, Gilead, Merck, Janssen, and Pfizer. C. A. B. has received payment for GSK board membership and Infectious Diseases Society of America board membership, speakers bureau, and travel and is an associate editor for Clinical Infectious Diseases; she has received grant funding to her institution from Gilead. T. W. has served as a paid consultant for ViiV/GSK and has received grant funding to his institution from ViiV/GSK, Gilead, and Bristol-Myers Squibb; his spouse holds stock options at Johnson & Johnson. S. L. K has received grant funding to her institution from Gilead. E. P. A. reported nonfinancial support from GSK/ViiV. J. Z. L. has served as a paid consultant and received grant funding from Gilead and Merck. P. E. S. has served as a paid consultant to Gilead, Abbvie, Merck, Janssen, ViiV/GSK, and Bristol-Myers Squibb, and has received grant funding to his institution from Gilead. All other authors report no potential conflicts. This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU). ViiV Healthcare and GlaxoSmithKline provided funding and the study drugs Acknowledgments. We acknowledge Patrick Janulis, Rachelle Price, Sherrie Wolfe, and Jane Regalado (Northwestern University); Cheryl Keenan (Brigham and Women’s Hospital); Kishna Outlaw, Hsin Chien, and the Emory Center for AIDS Research (P30AI050409) (Emory University); Heather Harber (The Ohio State University); Fran Hyc and Eva Whitehead (University of Cincinnati); Helen King, and Edward Seefried (University of California at San Diego); and Todd Stroberg and Valery Hughes (Weill Cornell Medicine). This publication was made possible with help from the Third Coast Center for AIDS Research (CFAR), an NIH funded center (P30 AI117943). Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at Northwestern University (NU), which is supported by the NU Clinical and Translational Science Institute, an NIH funded National Center for Advancing Translational Sciences (UL1TR001422).
Keywords
- 2-drug
- Dolutegravir
- lamivudine
- maintenance therapy
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
